Journal
UROLOGY
Volume 70, Issue 4, Pages 630-633Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2007.08.032
Keywords
-
Categories
Funding
- NCI NIH HHS [P50 CA090381] Funding Source: Medline
- NIA NIH HHS [R01AG21404, R01 AG021404] Funding Source: Medline
Ask authors/readers for more resources
OBJECTIVES To characterize the clonality of TMPRSS2-ERG fusion in multifocal prostate cancer. METHODS From 80 consecutive radical prostatectomy specimens, we identified 32 cases with multiple spatially separate tumors. In each case, we assessed two to three tumor foci for TMPRSS2-ERG fusion using an ERG break-apart interphase fluorescence in situ hybridization assay. RESULTS Individual tumor foci showed homogenity for fusion status (intrafocal clonal homogenity). In 19 (59%) of the 32 cases, all foci within a case had the same fusion status (interfocal homogeneity). In 15 (80%) of the 19 cases, no foci had fusion, and in 4 (20%), all foci had fusion. Of the 32 cased, 13 (41%) demonstrated heterogeneity for fusion status within a case (interfocal clonal heterogeneity). CONCLUSIONS In this study, we have demonstrated interfocal heterogeneity and intrafocal homogeneity for TMPRSS2-ERG fusion in prostate cancer with multiple tumors. These findings support the multiclonal nature of prostate cancer with clinical implications for needle biopsy strategies and the development of urine-based screening tests.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available